AI brings savings to clinical trials: study
TL;DR
Artificial intelligence isn't just speeding up early-stage drug development, it's starting to unlock millions of dollars' worth of new efficiencies in clinical trials on cancer treatments, research shared first with Axios shows. Why it matters: AI-powered tools could shave months off time-consuming processes like recruiting and enrolling patients, monitoring results and interpreting data. That could free up resources for more clinical studies and possibly lower the high failure rate for new drugs.
Nauti's Take
Pharma teams should test AI first in patient recruitment and data preparation, where time savings are easiest to measure. The figures come from a single Tufts analysis first reported by Axios, so the cost estimates still need independent validation.
Before changing budgets, teams should check the assumptions around tumor types, trial size, and human oversight.
Sources